Well, one issue down, a second one ready for prime time, and several more in various stages of preparation. And already we’re seeing changes. But then, whenever you try to accomplish any venture in the drug discovery arena—be it a new pill, instrument, or magazine—you have to be ready to move as the market moves.
Welcome to the first monthly issue of Drug Discovery News, a trade publication like no other in the drug discovery field. Over the past four months, it has been a pleasure immersing myself in the industry, all while attempting not to drown in the deluge of information. From the floors of Lab Automation 2005 in San Jose, to Pitttcon in Orlando and back to my office in Portland, Maine, my conversations with you have yielded a new vocabulary which only yield blank looks from my family at the end of the day when I start waxing poetic about RNAi, GPCRs, HPLC or MALDI MS.
Welcome to the April issue of Drug Discovery News. Just eight short months after the termination announcement of Modern Drug Discovery, former MDD executives and editors present you with a unique and exclusive format for industry news.
It’s a crowded market for trade publications covering drug discovery. We know that. We also know that in order to stand out in a crowd you need to be different. With that, we introduce you to Drug Discovery News a trade publication that’s more like the business section of your daily newspaper, than any other publication covering drug discovery. This is no “me too” publication that is feature rich, technology-focused and light on news.
Since 1986, Qiagen has developed and marketed a range of products for academic and industrial markets, including life science research, genomics, gene-based drug discovery, nucleic acid-based molecular diagnostics, genetic vaccination, and gene therapy market.
With the $11-million purchase of Transfluor technology assets from Xsira Pharmaceuticals in early March, Molecular Devices Corp. officials say the company significantly strengthened its position as a provider of tools for imaging and G-protein coupled receptor (GPCR) assays.
In an effort to speed adoption of the company’s flagship product,
the AFRICA flow microreactor, Syrris Inc. last month opened its first U.S. office in Ridgewood, N.J. smack in the heart of the East Coast pharmaceutical hotbed.
In early March, Upstate Group Inc. completed the expansion of its kinase screening and production facility here, more than doubling its previous size to meet demand for its services growing in a market where company officials say it captures more than 76 percent of the business.
Ambit Biosciences recently announced the appointments of Dr. Robert deGroof and Dr. Shripad Bhagwat to the positions of senior vice president of development and senior vice president of drug discovery, respectively.
In mid-February, Affinium Pharmaceuticals announced initial success of its Galapagos compound screening program in the identification of the first potential drug targeted against a novel bacterial pathway in almost 40 years.
Microarray company CombiMatrix and RNAi therapeutics firm Benitec entered into a broad cross-licensing and collaboration agreement in late February that makes virtually all of the two company’s patents and intellectual property available to each other for use in each firm’s research and development activities.
After a few years of funding academic research and observing advances in the burgeoning field of RNAi, Cystic Fibrosis Foundation Therapeutics (CFFT) Inc., recently announced its first funding of a commercial partner to initiate discovery research for a potential RNAi therapeutic for CF.
To push the frontiers of diabetes and obesity treatments, the US-based headquarters of Australian RNAi specialist Benitec recently signed an exclusive licensing agreement with the Garvan Institute of Medical Research, based in Sydney, Australia.
Instrumentation and discovery informatics provider Symyx Technologies Inc. announced in late February its intention to acquire Research Triangle Park, N.C.-based Synthematix, a provider of organic synthesis reaction software systems.
Scientists at the Lawrence Berkeley National Laboratory, in concert with other national labs across the country, recently launched an online microbial genome database that integrates for the first time all previously published sequence data from the Joint Genome Institute (JGI) and other public research arms.
Applied Biosystems and professional consulting services provider Deloitte Consulting LLP signed a strategic alliance agreement in late February that will allow the two companies to work in concert to provide comprehensive informatics solutions that reach from the bench to the boardroom.
Unwilling to simply sit on its laurels and coast along with what is reportedly the world’s largest commercial gene expression reference database, GeneLogic recently introduced its Microarray Data Generation and Analysis Services.
SciTegic Inc. announced in March an independent software vendor (ISV) partner program that is will allow the ISV’s tools and applications to run seamlessly on SciTegic’s flagship Pipeline Pilot informatics system.